AI-informed Drug Developer Moves from Boston to Medford


MEDFORD, Mass.– Unravel Biosciences will move this July from an incubator lab at UMASS Boston to 3,200 square feet of dedicated space in Medford. The firm’s new headquarters, situated within Cummings Properties’ Boston Avenue innovation campus, will house its administrative and research and development functions.

Founded in 2021, Unravel Biosciences is using AI to advance new therapies for complex diseases and central nervous system disorders. The firm’s proprietary BioNAVTM drug discovery platform, developed at Harvard University’s Wyss Institute, has already led to four clinical trials and an FDA orphan drug designation in 2024.

“Our signature Medford location and strong, longstanding affiliation with Tufts University were key factors in the decision,” said Senior Leasing Director Rob Yacobian of Cummings Properties. “Unravel’s new space offers convenient access to its partners at Tufts as well as a fertile recruiting ground to support its growing operations.”

Yacobian worked with Senior Advisor Brendan Entenmann, of the Steele Group brokerage firm, on the lease, which includes a custom renovation.

“We have strong working relationships in the brokerage community,” said Yacobian, “and collaborating with Brendan in particular made it seamless to come up with a lease arrangement that worked well for both parties.”

In addition to multiple labs operated by Tufts University, Unravel’s new neighbors on Boston Avenue include Morphoceuticals, Myro Therapeutics, Solu Therapeutics, and Sunflower Therapeutics.

The Medford innovation campus features move-in-ready lab and office space with upgraded finishes, free covered parking, and on-site MBTA bus access. The Green Line extension, as well as numerous eateries, shops, and other conveniences, are within close walking distance.